B1Q Stock Overview A clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
NRx Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for NRx Pharmaceuticals Historical stock prices Current Share Price US$4.86 52 Week High US$6.70 52 Week Low US$2.08 Beta 1.29 1 Month Change 0% 3 Month Change 2.53% 1 Year Change 11.98% 3 Year Change -95.79% 5 Year Change n/a Change since IPO -97.16%
Recent News & Updates
NRx Pharmaceuticals, Inc. Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression Dec 30
NRx Pharmaceuticals, Inc. Announces Chief Financial Officer Changes Nov 19
NRx Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 08
NRx Pharmaceuticals, Inc. Announces Chief Executive Officer Changes Oct 12
NRx Pharmaceuticals, Inc., Annual General Meeting, Oct 08, 2024 Aug 28
NRx Pharmaceuticals, Inc. Announces Resignation of Stephen Willard as Chief Executive Officer Aug 23 See more updates
NRx Pharmaceuticals, Inc. Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression Dec 30
NRx Pharmaceuticals, Inc. Announces Chief Financial Officer Changes Nov 19
NRx Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 08
NRx Pharmaceuticals, Inc. Announces Chief Executive Officer Changes Oct 12
NRx Pharmaceuticals, Inc., Annual General Meeting, Oct 08, 2024 Aug 28
NRx Pharmaceuticals, Inc. Announces Resignation of Stephen Willard as Chief Executive Officer Aug 23
NRx Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 14, 2024 Aug 14
NRx Pharmaceuticals Receives Letter from the Listing Qualifications Staff of the Nasdaq Regarding Market Value of Listed Securities Aug 13
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Announce Alignment with FDA on Pediatric Study Plan for NRX-100 (ketamine) Jul 29
NRx Pharmaceuticals, Inc. to Proceed with Two New Drug Applications in 2024 Jun 28
NRx Pharmaceuticals, Inc. Appoints Dennis McBride to Its Board of Directors Jun 18
NRx Pharmaceuticals, Inc. Presents Landmark Trial of Nrx-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: Nrx-101 Is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression May 29
NRx Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024 May 09
NRx Pharmaceuticals, Inc. Announces Final Clinical Trial Results May 08
NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression May 01
NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression Apr 30 NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $2.0031 million. Apr 20
NRx Pharmaceuticals Demonstrates Compliance with the Nasdaq Bid Price Requirement in Listing Rule 5550(a)(2) NRx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering. Apr 18
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics Apr 17
NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine) Apr 16
NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression Apr 09 NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing Mar 29
NRx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 28, 2024 Mar 22
NRX Pharmaceuticals Announces Last Patient, Last Visit in Its Phase 2B/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression Mar 05 NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million. Feb 28
NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million.
Panel Grants NRx Pharmaceuticals Request for an Exception to Nasdaq Listing Rules Until April 16, 2024, to Demonstrate Compliance with the Rule Jan 24
NRx Pharmaceuticals, Inc. Announces Completion of Enrollment of Its Phase 2b/3 Trial of NRx-101 in Suicidal Treatment Resistant Bipolar Depression Jan 23
NRx Pharmaceuticals, Inc. Announces FDA Qualified Infectious Disease Product and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis Jan 16
NRx Pharmaceuticals Demonstrates Compliance with Nasdaq MVLS Standard Jan 02
Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors Dec 27
NRx Pharmaceuticals, Inc. Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections Dec 18
NRx Pharmaceuticals, Inc., Annual General Meeting, Dec 19, 2023 Nov 23
NRx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023 Nov 08
NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain Oct 28
NRx Pharmaceuticals Receives Formal Notice from the Listing Qualifications Staff of Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Oct 24
NRx Pharmaceuticals Announces Strategic Acceleration of its Plans to Develop Commercial Form of NRX-100 (intravenous ketamine) to Treat Acute Depression and Suicidality Oct 13
NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain Oct 05 NRX Pharmaceuticals, Inc. Appoints Richard Narido, as Principal Financial Officer and Principal Accounting Officer
NRx Pharmaceuticals, Inc. Announces New Data That Demonstrates Potent in Vitro Activity of NRx-101 Sep 07
NRx Pharmaceuticals Announces Submission of an Investigational New Drug Application for NRX -101 in the Treatment of Chronic Pain Aug 31 NRx Pharmaceuticals, Inc. announced that it expects to receive $1.2 million in funding Aug 30
Co-Founder recently bought €59k worth of stock Aug 24
NRx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023 Aug 08
NRx Pharmaceuticals Receives Written Notification from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5450(b)(2)(A) – Market Value of Listed Securities Jul 30 NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $6.285501 million. Jun 13
NRx Pharmaceuticals, Inc. Reports Minutes of U.S. Food and Drug Administration Meeting on Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality Feb 14
NRx Pharmaceuticals, Inc. Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101 Jan 20
NRx Pharmaceuticals, Inc. Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted Jan 04
Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc. Dec 22
CEO & Director recently bought €55k worth of stock Dec 20
Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announces Close of Definitive Settlement Agreements Dec 20
High number of new and inexperienced directors Nov 23
NRx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022 Nov 11
NRx Pharmaceuticals, Inc. Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process Nov 10 NRx Pharmaceuticals, Inc. announced that it has received $10 million in funding Nov 09
NRx Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 15, 2022 Aug 11
NRx Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Jul 16 NRx Pharmaceuticals, Inc. Announces the Appointment of Stephen Willard as its Chief Executive Officer
Nrx Pharmaceuticals, Inc. Announces FDA Declines Emergency Use Authorization for Zyesami® (Aviptadil) for Subgroup of Patients with Critical Covid-19 At Immediate Risk of Death from Respiratory Failure Despite Treatment with Approved Therapy, Including Remdesivir Jul 02 Shareholder Returns B1Q DE Pharmaceuticals DE Market 7D 0% 2.3% 1.4% 1Y 12.0% -14.5% 9.1%
See full shareholder returns
Return vs Market: B1Q exceeded the German Market which returned 4.2% over the past year.
Price Volatility Is B1Q's price volatile compared to industry and market? B1Q volatility B1Q Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 5.6% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: B1Q has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine B1Q's volatility change over the past year.
About the Company NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital.
Show more NRx Pharmaceuticals, Inc. Fundamentals Summary How do NRx Pharmaceuticals's earnings and revenue compare to its market cap? B1Q fundamental statistics Market cap €26.67m Earnings (TTM ) -€23.88m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) B1Q income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$25.65m Earnings -US$25.65m
Last Reported Earnings
Mar 31, 2024
Earnings per share (EPS) -2.39 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -45.0%
How did B1Q perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/06/25 05:19 End of Day Share Price 2024/03/28 00:00 Earnings 2024/03/31 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources NRx Pharmaceuticals, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Edward Woo Ascendiant Capital Markets LLC Jason Kolbert D. Boral Capital LLC. Vernon Bernardino H.C. Wainwright & Co.
Show 0 more analysts 